---
schema_version: "secwatch.filing_event.v1"
accession: "0001562762-22-000187"
form_type: "8-K"
ticker: "GMED"
cik: "0001237831"
company_name: "GLOBUS MEDICAL INC"
filed_at: "2022-04-21T23:59:59+00:00"
generated_at: "2026-06-26T05:36:47.616165+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Globus Medical names Dan Scavilla as CEO replacing Demski; prelim Q1 sales $230.5M +1.4% YoY

## Summary
- David Demski resigned as CEO effective April 21, 2022; not due to any disagreement; will assist transition through June 30.
- Daniel T. Scavilla appointed President & CEO; previously EVP Chief Commercial Officer and President of Trauma.
- Preliminary Q1 2022 sales approx. $230.5M, up 1.4% vs Q1 2021; full-year 2022 guidance reaffirmed: $1.025B sales, non-GAAP EPS $2.10.
- Scavilla's base salary increased to $450K; target annual non-equity incentive to $900K; receives option for 60,000 shares vesting 4 years.

## SEC filing metadata
- accession: 0001562762-22-000187
- form_type: 8-K
- ticker: GMED
- cik: 0001237831
- company_name: GLOBUS MEDICAL INC
- filed_at: 2022-04-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1237831/000156276222000187/0001562762-22-000187-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1237831/000156276222000187/gmed-20220421x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001562762-22-000187
- JSON: https://secwatch.observer/filing/0001562762-22-000187.json
- Plain text: https://secwatch.observer/filing/0001562762-22-000187.txt

## Key facts
- Executive change
  David M. Demski resigned as President and Chief Executive Officer at GLOBUS MEDICAL INC.
  - Action: resigned
  - Role: President and Chief Executive Officer
  source text: On April 20, 2022, Mr. Demski also notified the Board of his resignation as President and Chief Executive Officer of the Company, effective April 21, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1237831/000156276222000187/0001562762-22-000187-index.htm
- Executive change
  Daniel T. Scavilla was appointed as President and Chief Executive Officer at GLOBUS MEDICAL INC.
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On April 21, 2022, the Board of Directors of the Company approved the appointment of Daniel T. Scavilla as President and Chief Executive Officer, effective April 21, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1237831/000156276222000187/0001562762-22-000187-index.htm
- Executive change
  Daniel T. Scavilla was appointed as Director at GLOBUS MEDICAL INC.
  - Action: appointed
  - Role: Director
  source text: On April 21, 2022, the Board appointed Mr. Scavilla to serve as a member of the Board and as a member of the Nominating and Corporate Governance Committee with a term expiring at the Company’s annual meeting in 2023 to fill the vacancy created by the resignation of Mr. Demski.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1237831/000156276222000187/0001562762-22-000187-index.htm
- Executive change
  David M. Demski resigned as Director at GLOBUS MEDICAL INC.
  - Action: resigned
  - Role: Director
  source text: On April 20, 2022, David M. Demski notified the Chairman of the Board of Directors (the “Board”) of the Company of his resignation from the Board effective April 20, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1237831/000156276222000187/0001562762-22-000187-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.